129 related articles for article (PubMed ID: 25948777)
1. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men.
Ribback S; Cigliano A; Kroeger N; Pilo MG; Terracciano L; Burchardt M; Bannasch P; Calvisi DF; Dombrowski F
Oncotarget; 2015 May; 6(15):13036-48. PubMed ID: 25948777
[TBL] [Abstract][Full Text] [Related]
2. Network Analysis and Basic Experiments on the Inhibition of Renal Cancer Proliferation and Migration by Alpinetin through PI3K/AKT/ mTOR Pathway.
Guo Y; Jiang L; Luo S; Hu D; Zhao X; Zhao G; Tang W
Curr Mol Med; 2024; 24(1):134-144. PubMed ID: 37221689
[TBL] [Abstract][Full Text] [Related]
3. CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling.
Chen X; Zhang T; Ren X; Wei Y; Zhang X; Zang X; Ju X; Qin C; Xu D
Eur J Med Res; 2023 Dec; 28(1):588. PubMed ID: 38093375
[TBL] [Abstract][Full Text] [Related]
4. Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.
Zhu Q; Zhong AL; Hu H; Zhao JJ; Weng DS; Tang Y; Pan QZ; Zhou ZQ; Song MJ; Yang JY; He JY; Liu Y; Li M; Hu WM; Yang CP; Xiang T; Chen MY; Ma G; Guo L; Xia JC
J Hematol Oncol; 2020 Jan; 13(1):2. PubMed ID: 31900208
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.
Badoiu SC; Greabu M; Miricescu D; Stanescu-Spinu II; Ilinca R; Balan DG; Balcangiu-Stroescu AE; Mihai DA; Vacaroiu IA; Stefani C; Jinga V
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176098
[TBL] [Abstract][Full Text] [Related]
6. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mTOR Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma.
Wang X; Yao L; Li Z; Zhang J; Ruan M; Mulati Y; Gan Y; Zhang Q
Int J Biol Sci; 2024; 20(2):643-663. PubMed ID: 38169650
[No Abstract] [Full Text] [Related]
7. Dysregulation of PI3K-Akt-mTOR pathway in brain of streptozotocin-induced type 2 diabetes mellitus in Wistar rats.
Bathina S; Das UN
Lipids Health Dis; 2018 Jul; 17(1):168. PubMed ID: 30041644
[TBL] [Abstract][Full Text] [Related]
8. P4HA3 promotes clear cell renal cell carcinoma progression via the PI3K/AKT/GSK3β pathway.
Zhang Z; Zhang Y; Zhang R
Med Oncol; 2023 Jan; 40(2):70. PubMed ID: 36588128
[TBL] [Abstract][Full Text] [Related]
9. DAB2IP stabilizes p27
Zhou J; Deng Z; Pei X; Lai J; Qu W
Funct Integr Genomics; 2023 Oct; 23(4):326. PubMed ID: 37880458
[TBL] [Abstract][Full Text] [Related]
10. Hormonally Induced Hepatocellular Carcinoma in Diabetic Wild Type and Carbohydrate Responsive Element Binding Protein Knockout Mice.
Nuernberger V; Mortoga S; Metzendorf C; Burkert C; Ehricke K; Knuth E; Zimmer J; Singer S; Nath N; Karim M; Yasser M; Calvisi DF; Dombrowski F; Ribback S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685767
[TBL] [Abstract][Full Text] [Related]
11. Endothelial Progenitor-Cell-Derived Exosomes Induced by Astragaloside IV Accelerate Type I Diabetic-wound Healing via the PI3K/AKT/mTOR Pathway in Rats.
Xiong W; Bai X; Zhang X; Lei H; Xiao H; Zhang L; Xiao Y; Yang Q; Zou X
Front Biosci (Landmark Ed); 2023 Nov; 28(11):282. PubMed ID: 38062822
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
Tehranian C; Fankhauser L; Harter PN; Ratcliffe CDH; Zeiner PS; Messmer JM; Hoffmann DC; Frey K; Westphal D; Ronellenfitsch MW; Sahai E; Wick W; Karreman MA; Winkler F
Neuro Oncol; 2022 Feb; 24(2):213-225. PubMed ID: 34216217
[TBL] [Abstract][Full Text] [Related]
13. The PI3K/AKT Pathway and Renal Cell Carcinoma.
Guo H; German P; Bai S; Barnes S; Guo W; Qi X; Lou H; Liang J; Jonasch E; Mills GB; Ding Z
J Genet Genomics; 2015 Jul; 42(7):343-53. PubMed ID: 26233890
[TBL] [Abstract][Full Text] [Related]
14. FAP promotes clear cell renal cell carcinoma progression via activating the PI3K/AKT/mTOR signaling pathway.
Jiang K; Xu LZ; Ning JZ; Cheng F
Cancer Cell Int; 2023 Sep; 23(1):217. PubMed ID: 37752545
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas.
Moldvai D; Sztankovics D; Dankó T; Vetlényi E; Petővári G; Márk Á; Patonai A; Végső G; Piros L; Hosszú Á; Pápay J; Krencz I; Sebestyén A
Br J Cancer; 2024 Apr; 130(7):1119-1130. PubMed ID: 38341510
[TBL] [Abstract][Full Text] [Related]
16. Genetic variants in the mTOR pathway with renal cancer risk and subtypes in East Indian population.
Malakar S; Chatterjee S; Das M; Pal DK
Urologia; 2024 May; 91(2):270-275. PubMed ID: 38205940
[TBL] [Abstract][Full Text] [Related]
17. Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.
Tsuchida A; Senda M; Ito A; Saito S; Kiso M; Ando T; Harduin-Lepers A; Matsuda A; Furukawa K; Furukawa K
Sci Rep; 2018 May; 8(1):7017. PubMed ID: 29728594
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Ballooning is Due to Highly Pronounced Glycogenosis Potentially Associated with Steatosis and Metabolic Reprogramming.
Ribback S; Peters K; Yasser M; Prey J; Wilhelmi P; Su Q; Dombrowski F; Bannasch P
J Clin Transl Hepatol; 2024 Jan; 12(1):52-61. PubMed ID: 38250461
[TBL] [Abstract][Full Text] [Related]
19. Retracted: Oleuropein Improves Cognitive Dysfunction and Neuroinflammation in Diabetic Rats through the PI3K/Akt/mTOR Pathway.
And Biomechanics AB
Appl Bionics Biomech; 2023; 2023():9813730. PubMed ID: 38075082
[TBL] [Abstract][Full Text] [Related]
20. Erratum to Associations between the polymorphisms of main components in PI3K/Akt pathway and risk of diabetic kidney disease: A meta-analysis.
IUBMB Life; 2024 Feb; 76(2):103. PubMed ID: 37650586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
